TGTX — TG Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $5.35bn
- $5.46bn
- $616.29m
Annual cashflow statement for TG Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -348 | -198 | 12.7 | 23.4 | 447 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 64.2 | 23.3 | 40.2 | 45.3 | 64.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -12 | -1.44 | -84.4 | -109 | -188 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -296 | -176 | -31.4 | -40.5 | -24.8 |
| Capital Expenditures | -0.401 | -0.014 | 0 | -0.045 | -0.214 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.069 | -20 | -50.7 | -0.991 | 14 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.332 | -20 | -50.7 | -1.04 | 13.8 |
| Financing Cash Flow Items | -1.02 | 0 | -0.125 | -0.889 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 41.4 | -0.391 | 72.7 | 129 | -89.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -255 | -197 | -9.36 | 87 | -101 |